This first-in-region economic evaluation concludes that sugemalimab plus CAPOX fails to demonstrate cost-effectiveness versus CAPOX monotherapy in first-line treating unresectable locally advanced/metastatic GC/GEJC regardless of PD-L1 expression levels under Chinese healthcare payer perspective. The gene discussed is CD274; the disease is gastric cancer.